IceCure Medical (NASDAQ:ICCM) Raised to “Hold” at Zacks Research

IceCure Medical (NASDAQ:ICCM) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday, Zacks reports.

Several other research analysts also recently commented on the stock. Wall Street Zen downgraded shares of IceCure Medical from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a research report on Friday, July 17th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, IceCure Medical has a consensus rating of “Hold” and a consensus target price of $30.00.

IceCure Medical Trading Up 1.9%

ICCM stock opened at $1.10 on Monday. The firm has a 50 day moving average of $2.15 and a 200-day moving average of $4.86. IceCure Medical has a 12 month low of $1.03 and a 12 month high of $26.97. The firm has a market capitalization of $3.77 million, a P/E ratio of -0.13 and a beta of 0.43.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings data on Tuesday, June 30th. The company reported ($1.60) EPS for the quarter. The firm had revenue of $0.91 million for the quarter. IceCure Medical had a negative net margin of 427.67% and a negative return on equity of 174.26%. Sell-side analysts predict that IceCure Medical will post -4.61 EPS for the current year.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is an Israel-based medical technology company that develops minimally invasive cryoablation systems for the treatment of tumors. Its technology uses liquid nitrogen to freeze and destroy targeted tissue, with the goal of providing an alternative to surgical removal in selected patients.

The company’s primary product is the ProSense system, which is designed to deliver controlled cryoablation through a probe inserted into a tumor. IceCure has focused on applications in breast, kidney, lung, and other solid tumors, including procedures performed under image guidance.